NEW YORK, NY--(Marketwire - Jan 5, 2012) - The always volatile biotechnology industry had its share of winners and losers last year. Overall, the biotech space was up more than 9 percent in 2011, CNBC reports. However several firms struggled immensely over the last year as disappointing revenues and FDA disappointments weighed down shares of several biotech companies. The Bedford Report examines the outlook for companies in the biotechnology industry and provides investment research on Cell Therapeutics, Inc. (NASDAQ: [ CTIC ]) and BioSante Pharmaceuticals, Inc. (NASDAQ: [ BPAX ]). Access to the full company reports can be found at:

[ www.bedfordreport.com/CTIC ]

[ www.bedfordreport.com/BPAX ]

Cell Therapeutics is a biopharmaceutical company committed to developing an integrated portfolio of oncology products aimed at making cancer more treatable. On Tuesday shares of the company traded at close to double their average volume after a Food and Drug Administration panel of experts said it will review CTI's resubmitted application for the potential cancer treatment pixantrone on Feb. 9. Cell Therapeutics says that pixantrone is for the treatment of relapsed or refractory aggressive non-Hodgkin's lymphoma (NHL) in patients who failed two or more lines of prior therapy.

The FDA failed to approve pixantrone in 2010 due to concerns that clinical trials did not show the drug was effective.

The Bedford Report releases stock research on the Biotechnology industry so investors can stay ahead of the crowd and make the best investment decisions to maximize their returns. Take a few minutes to register with us free at [ www.bedfordreport.com ] and get exclusive access to our numerous stock reports and industry newsletters.

Shares of BioSante collapsed in late-2011 after the company's female sexual dysfunction drug LibiGel failed in two late-stage clinical trials. "We obviously are very disappointed by the Phase III LibiGel efficacy trial results. We have been committed to LibiGel for many years and we are committed to determining the future of LibiGel," stated Stephen M. Simes, BioSante's president & CEO.

While the enthusiasm for LibiGel has died down, BioSante is also developing a portfolio of cancer vaccines, four of which have been granted Orphan Drug designation, and are currently in several Phase II clinical trials.

The Bedford Report provides Market Research focused on equities that offer growth opportunities, value, and strong potential return. We strive to provide the most up-to-date market activities. We constantly create research reports and newsletters for our members. The Bedford Report has not been compensated by any of the above-mentioned companies. We act as an independent research portal and are aware that all investment entails inherent risks. Please view the full disclaimer at: [ http://www.bedfordreport.com/disclaimer ]